In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis

J Med Microbiol. 2018 Sep;67(9):1217-1220. doi: 10.1099/jmm.0.000801. Epub 2018 Jul 17.

Abstract

The in vitro activity of anti-pseudomonal β-lactams in combination with avibactam was evaluated against 54 multidrug-resistant non-fermenting Gram-negative bacilli isolated from cystic fibrosis patients. Avibactam increased and/or restored the antibacterial activities of ceftazidime and aztreonam against Pseudomonas aeruginosa and Stenotrophomonas maltophilia, respectively. No β-lactam-avibactam combination was active against Achromobacter xylosoxidans.

Keywords: Achromobacter; Pseudomonas; Stenotrophomonas; avibactam; cystic fibrosis; β-lactam.

MeSH terms

  • Achromobacter denitrificans / drug effects*
  • Achromobacter denitrificans / genetics
  • Achromobacter denitrificans / isolation & purification
  • Anti-Bacterial Agents / pharmacology*
  • Azabicyclo Compounds / pharmacology*
  • Cystic Fibrosis / microbiology*
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / genetics
  • Pseudomonas aeruginosa / isolation & purification
  • Stenotrophomonas maltophilia / drug effects*
  • Stenotrophomonas maltophilia / genetics
  • Stenotrophomonas maltophilia / isolation & purification
  • beta-Lactams / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • beta-Lactams
  • avibactam